These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.